Despite more than 600 reports of "adverse events" for medicinal cannabis in the past three years, the Therapeutic Goods Administration (TGA) is yet to investigate the safety of most medicinal cannabis products. It has now launched a review.

The whole article is worth reading but this caught my eye.

The Australian Medicinal Cannabis Association (AMCA) said that without suspected adverse events being published and investigated it was hard to draw conclusions about the safety of medicinal cannabis products.

If the only organisation representing cannabis prescribers is unwilling to comment on safety what does that say about the state of the industry?

    • Joshi@slrpnk.netOPEnglish
      2·
      16 days ago

      I would suggest that corporate practices going gungho prescribing medications without established safety data is more concerning than a potential prescriber impatiently waiting for the TGA to get their act together and assess these medications.